Clinical trials
Meropenem clinical trials
Below are recruiting meropenem clinical trials, each written for real people, not researchers. We’re tracking 20 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07004049RecruitingPhase 4
Testing combinations for resistant Gram-negative infections
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
Brisbane, QueenslandAges 18 years+ - NCT07089186RecruitingPhase 3
Study of meropenem and pralurbactam for certain antibiotic-resistant infections
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
ShanghaiAges 18–80 - NCT06426836Recruiting
Better antibiotic dosing for children on ECMO
This trial studies how to give the right dose of common antibiotics to children on ECMO (a heart-lung bypass machine). The goal is to help doctors choose the best dose to fight infections while keeping the child safe.
Brussels, Brussels CapitalAges Up to 15 years - NCT07327619RecruitingPhase 3
Testing a New Antibiotic Combo for Hospital-Acquired Pneumonia
This trial tests a combination of two antibiotics (meropenem and pralurbactam) to see if they work better than other treatments for people with pneumonia that started in the hospital or from a breathing machine. If you qualify, this study might offer you a new treatment option.
Huaihua, HunanAges 18–80 - NCT05922124RecruitingPhase 4
Testing two antibiotics against resistant lung and bloodstream infections
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
HaifaAges 16 years+ - NCT02456974Recruiting
Testing how antibiotics are dosed in children’s intensive care
This study looks at whether giving common antibiotics in certain dose schedules (either through a drip over time or continuously) is done in a way that fits pediatric intensive care needs. It may help improve antibiotic treatment for children who are very sick and need antibiotics.
GhentAges 1 day–16 years - NCT03671967RecruitingPhase 4
Compare two antibiotics for hard-to-treat E. coli and Klebsiella bloodstream infections
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
Calgary, AlbertaAges 18 years+ - NCT05578586Recruiting
Study testing how to give meropenem in the ICU
This pilot study looks at the best way to give meropenem antibiotic to ICU patients with a serious suspected or confirmed infection. It may help improve treatment timing and dosing to fight infection while in intensive care.
OsloAges 18 years+ - NCT06184659RecruitingPhase 4
Comparing two antibiotics for sepsis in critical illness
This trial compares two common antibiotics, meropenem and piperacillin/tazobactam, to see which works better for adults with sepsis who are critically ill. It aims to help doctors choose the best treatment for serious infections.
Copenhagen, København ØAges 18 years+ - NCT06293677RecruitingPhase 4
Antibiotic Dosing for Kids With Cancer and Fever
This study tests whether adjusting antibiotic doses based on how fast your kidneys clear the medicine can better treat infections in children with cancer who have a fever and low white blood cells (neutropenia). It aims to improve recovery and reduce side effects.
Lausanne, Canton of VaudAges 2 months–18 years - NCT06342115RecruitingPhase 4
Ceftolozane/tazobactam vs meropenem for febrile neutropenia with ESBL risk
This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.
São PauloAges 18 years+ - NCT07124468RecruitingPhase 1
Antibiotic levels in lungs of healthy adults
This trial tests how a new antibiotic (meropenem-pralubactam) moves into the lungs of healthy people in China. You will receive the medicine through an IV, and a lung fluid sample will be collected to measure the drug levels.
FuzhouAges 18–45 - NCT07314281RecruitingPhase 4
Comparing two antibiotics for XDR typhoid fever
This trial compares two strong antibiotics, meropenem (given through a vein) and azithromycin (taken by mouth), to see which one works better for a hard-to-treat type of typhoid fever called XDR (extensively drug-resistant) enteric fever. If you have been diagnosed with XDR typhoid fever, this study aims to find the best treatment option for you.
Karachi, SindhAges 1–70 - NCT07556107RecruitingPhase 4
Safety study of two antibiotics for serious hospital infections
This study watches how safely two common antibiotics (vancomycin and a combination called piperacillin/tazobactam) work together in hospitalized patients with serious infections. Researchers want to make sure the combination doesn't harm kidney function.
Cooperstown, New YorkAges 18 years+ - NCT05426499Recruiting
Modeling how pediatric anti-infective drugs behave in kids
This trial studies how certain anti-infective medicines (for bacterial and fungal infections) move through the body in children. The goal is to use that information to improve how these medicines are dosed and used safely in pediatric care.
Poznan, Greater Poland VoivodeshipAges Any age - NCT07326540RecruitingPhase 3
Testing a new antibiotic for drug-resistant pneumonia in the hospital
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
TbilisiAges 18–82 - NCT06841731RecruitingPhase 2
Testing a new antibiotic for hospital-acquired pneumonia
This trial tests a new antibiotic called HRS-8427 for adults with bacterial pneumonia that started in the hospital or while on a ventilator. It may be an option if you need IV antibiotics and haven't already received long-term treatment for this infection.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06828848RecruitingPhase 2
Study of Vaborem in children with Gram negative infections
This trial tests how Vaborem is absorbed and tolerated in children with serious bacterial infections, including complicated urinary tract infections. It aims to find the right dose for children.
OstravaAges birth–17 years - NCT05565222RecruitingPhase 3
Testing two antibiotics as alternatives for ICU severe ESBL infections
This study compares two antibiotics—piperacillin-tazobactam or temocillin—to treat severe ICU infections caused by certain hard-to-treat gut bacteria (ESBL). It may help patients avoid the use of carbapenem antibiotics like meropenem when the bacteria are susceptible.
ParisAges 18 years+ - NCT05925309Recruiting
Oral antibiotics to prevent bile duct inflammation after Kasai surgery
This trial studies whether giving oral antibiotics before symptoms start can lower the chance of cholangitis (bile duct infection/inflammation) after Kasai portoenterostomy. It may help protect your child’s bile flow and reduce painful or serious infections after surgery.
Shanghai, Shanghai MunicipalityAges 2 weeks–3 months
Hear when a new Meropenem trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for meropenem?
- Yes. Clin2 currently lists 20 recruiting meropenem studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a meropenem trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a meropenem trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.